Clinical Trial Update: Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating short-course radiotherapy followed by disitamab vedotin with S-1 and sintilimab for HER2-expressed locally progressive gast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• RC48-ADC (Disitamab Vedotin)
• S-1 (tegafur/gimeracil/oteracil)
• Tyvyt (Sintilimab)

Snippet

Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Conditions: Gastric Cancer | Phase 2 | Status: RECRUITING